Antonello Joseph M, Murphy Rocio D, Abeygunawardana Chitrananda, Malinverni Juliana C, Gowrisankar Rajam, Green Tina, Greway Rebecca, Schmauch Jenna, Howlett Adrienne, Bonhomme Cyrille J, Nolan Katrina M
Merck & Co., Inc., Rahway, New Jersey, USA.
PPD Vaccine Sciences, part of Thermo Fisher Scientific, Richmond, Virginia, USA.
mSphere. 2025 Jan 28;10(1):e0040424. doi: 10.1128/msphere.00404-24. Epub 2025 Jan 7.
Measuring the immunogenicity of pneumococcal vaccines involves the use of immunoassays to measure serotype-specific immunoglobulin G (IgG) antibody levels post-vaccination with the current human reference serum standard (007sp) for anti-pneumococcal capsule antibodies. Development of new pneumococcal conjugate vaccines (PCVs) with additional serotypes not in 007sp (e.g., V116, a 21-valent PCV) requires a new reference serum. Antibody concentrations to 33 pneumococcal serotypes were assigned in a new Merck Pneumococcal Reference Serum Standard (MPRSS-01; Merck Pneumococcal Reference Serum Standard) using the pneumococcal electrochemiluminescence assay. MPRSS-01 was generated by pooling high-titer serum samples from adults immunized with either 23-valent pneumococcal polysaccharide vaccine (PPSV23) or V116. For the 24 serotypes with established IgG concentrations, the corresponding antibody concentrations in MPRSS-01 were assigned via direct calibration to 007sp, while a cross-standardization approach was used for the nine novel serotypes. Serotype 7F was initially chosen as the reference calibrator for cross-standardization due to parallelism across dilution-response curves demonstrated across all 33 serotypes, and an evaluation of the single-calibrator approach was conducted for the 24 serotypes. Potential systematic bias from using a unique serotype for calibration was identified and addressed by further adjusting the estimated IgG concentrations of the nine novel serotypes. Using the final MPRSS-01 antibody concentration assignments, and the calibration factor relating MPRSS-01 to 007sp, antibody concentration assignments for 007sp were provided for the nine novel serotypes. This proposal was accepted by the Center for Biologics Evaluation and Research (CBER), enabling V116 to bridge old and new human pneumococcal reference sera.IMPORTANCEImmunogenicity of pneumococcal vaccines is measured using post-vaccination serotype-specific immunoglobulin G (IgG) antibodies in serum using enzyme-linked immunoassays with the 007sp reference serum containing serotype-specific IgG for 24 pneumococcal serotypes. With the development of next-generation PCVs, a new reference serum standard was needed to include serotypes beyond the existing 24 in 007sp. In this study, antibody concentrations to 33 pneumococcal serotypes were assigned in a new Merck Pneumococcal Reference Serum Standard (MPRSS-01) using the pneumococcal electrochemiluminescence assay, enabling V116 to maintain the link to the historical human pneumococcal standard reference serum while utilizing the new human pneumococcal reference serum.
测量肺炎球菌疫苗的免疫原性涉及使用免疫测定法,以当前用于抗肺炎球菌荚膜抗体的人类参考血清标准品(007sp)来测量接种疫苗后血清型特异性免疫球蛋白G(IgG)抗体水平。开发含有007sp中未包含的额外血清型的新型肺炎球菌结合疫苗(PCV)(例如21价PCV V116)需要一种新的参考血清。使用肺炎球菌电化学发光测定法,在新的默克肺炎球菌参考血清标准品(MPRSS - 01;默克肺炎球菌参考血清标准品)中确定了针对33种肺炎球菌血清型的抗体浓度。MPRSS - 01是通过汇集接种23价肺炎球菌多糖疫苗(PPSV23)或V116的成年人的高滴度血清样本而产生的。对于24种已确定IgG浓度的血清型,MPRSS - 01中相应的抗体浓度通过直接校准至007sp来确定,而对于9种新型血清型则采用交叉标准化方法。由于在所有33种血清型中稀释 - 反应曲线具有平行性,最初选择血清型7F作为交叉标准化的参考校准物,并对24种血清型进行了单校准方法的评估。通过进一步调整9种新型血清型的估计IgG浓度,识别并解决了使用单一血清型进行校准可能产生的系统偏差。利用最终的MPRSS - 01抗体浓度赋值以及将MPRSS - 01与007sp相关联的校准因子,为9种新型血清型提供了007sp的抗体浓度赋值。该提议被生物制品评估和研究中心(CBER)接受,使得V116能够连接新旧人类肺炎球菌参考血清。重要性肺炎球菌疫苗的免疫原性是通过酶联免疫测定法,使用含有24种肺炎球菌血清型特异性IgG的007sp参考血清,来测量接种疫苗后血清中血清型特异性免疫球蛋白G(IgG)抗体。随着下一代PCV的开发,需要一种新的参考血清标准品来纳入007sp中现有的24种血清型之外的血清型。在本研究中,使用肺炎球菌电化学发光测定法在新的默克肺炎球菌参考血清标准品(MPRSS - 01)中确定了针对33种肺炎球菌血清型的抗体浓度,使得V116能够在利用新的人类肺炎球菌参考血清的同时,保持与历史人类肺炎球菌标准参考血清的联系。